E-6837

E-6837 is a novel, selective and high-affinity 5-HT6 receptor ligand (reported pKi around 9.1) that, in functional cAMP assays, acts as a partial agonist at the ordinarily silent rat 5-HT6 receptor and as a full agonist at the constitutively active human receptor ^[2]. It was developed at Laboratorios Dr. Esteve alongside its analogue E-6801 as part of a programme that used forskolin stimulation and constitutively active receptor mutants to resolve the true efficacy of 5-HT6 ligands ^[2].

E-6837's most distinctive contribution is metabolic. In diet-induced obese rats, chronic oral administration produced sustained body-weight loss and decreased cumulative food intake over a four-week treatment period, with the reference anti-obesity drug sibutramine used as a comparator; E-6837 had a slower onset but a greater maximal effect, reducing body weight by roughly 16 percent versus about 11 percent for sibutramine ^[1]. The weight loss was driven almost entirely by a reduction in fat mass, accompanied by a fall in plasma leptin and improved glycemic control, and although weight regain occurred after withdrawal, body weights remained lower than after sibutramine, indicating less rebound hyperphagia ^[1].

These findings positioned E-6837 as evidence that central 5-HT6 modulation can regulate appetite and body weight, complementing the receptor's better-known cognitive roles and echoing observations that even the antagonist idalopirdine reduces food intake in obesity models ^[1]. E-6837 was not developed clinically and is a research compound, but it remains a notable example of 5-HT6-based approaches to obesity ^[1][2].

As a preclinical research compound, E-6837 has no established human safety profile. In rodent obesity studies chronic dosing was tolerated and produced weight loss without the profound rebound seen with some comparators, but it is not intended for human consumption and lacks any clinical tolerability data.

E-6837 was developed by Laboratorios Dr. Esteve in Spain in the mid-2000s together with E-6801, and it was characterized both in the foundational 5-HT6 efficacy studies and in a dedicated diet-induced obesity model comparing it with sibutramine. It remained a research compound and did not advance to clinical development.

E-6837 is recognized in the 5-HT6 literature as a key demonstration that the receptor is a plausible anti-obesity target, and it is frequently cited when discussing the metabolic, as opposed to cognitive, dimensions of 5-HT6 pharmacology. It has no standing as a consumer product and is a research chemical.